Hogan Lovells has advised the shareholders of UK-based Internis Pharmaceuticals on its sale to German pharmaceutical company Stada Arzneimittel for £49 million.

The sale included Internis Pharmaceuticals’ Fultium-D3 prescription medicine for treating vitamin D3 deficiency.

The Hogan Lovells team acting for Internis Pharmaceuticals shareholders was led by Ed Harris (partner) assisted by Ollie Vallee, Suzy Penney, Holly Hirst and Dan Won on the Corporate aspects; Paul Joukador, George Jenkins, Jane Summerfield and Oliver Wilson on Commercial aspects; Philip Harle and Christopher Hyde on Tax aspects and Kiran Khetia on Employee Benefit aspects.